Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,629.00
(
0.16%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rstor1 post# 4278

Friday, 10/22/2004 10:42:08 AM

Friday, October 22, 2004 10:42:08 AM

Post# of 257266
Re: DYAX:

Today’s steep drop is fallout from the company’s having set expectations too high for the DX-88 program in HAE. Astute posters such as iHub’s snorkel (a.k.a. Norman Klein from the Yahoo GTCB board) have asserted for some time that there was no way the FDA would entertain a BLA in this indication based on DYAX’s skimpy phase-2 program. From today’s PR, it’s clear that this view was correct.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today